Clinical trials: MGUS
Monoclonal Gammopathy, Smoldering Myeloma
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve…
- Conditions
- Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
- Trial name
- NCT03591614
- Testing
- DKK1
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma.
- Trial name
- NCT00006219
- Testing
- clarithromycin, prasterone
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
Anti MAG Neuropathy
This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG)
Patients treated in the hematology department of the Quimper/Cornouaille Hospital Center for IgM monoclonal gammopathy with anti-MAG and symptomatic peripheral neuropathy often reach a therapeutic impasse.
- Trial name
- LASER-MAG (NCT07661667)
- Testing
- photobiomodulation
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier de Cornouaille
Waldenstrom Macroglobulinemia
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
Multicenter retrospective and prospective observational study including patients with WM or IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly sensitive techniques.
- Trial name
- FIL_BIOWM (NCT03521596)
- Testing
- MRD and clonal evolution
- Where
- 15 sites in Italy, Spain
- Volunteers
- 300 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Schnitzler Syndrome
Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Schnitzler syndrome is a disabling inflammatory disease, characterized by chronic urticaria, fever, arthralgia, bone pain and gammopathy, which can so far only be effectively treated with anakinra, an interleukin-1 receptor…
- Trial name
- NCT01276522
- Testing
- Canakinumab
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Radboud University Medical Center
Precancerous Condition
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
This study was done to find out if the investigational medication, rituximab, could help relieve the symptoms of peripheral neuropathy (such as numbness [abnormal protein in the blood] and weakness of the lower and upper…
- Trial name
- NCT00588822
- Testing
- Rituximab
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Polyneuropathy
RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years.
- Trial name
- NCT00259974
- Testing
- Rituximab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein)…
- Trial name
- CHAPERONE (NCT05965115)
- Testing
- Sample of Blood
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Waldenstrom Macroglobulinemia
Spanish Registry of Patients With IgM Monoclonal Gammopathies
Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder which is defined by bone marrow infiltration by small lymphocytes, lymphoplasmacytoid and plasma cells together with the presence of a detectable…
- Trial name
- PRAME (NCT05093153)
- Where
- 51 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
IgA Monoclonal Gammopathy of Undetermined Significance, Non-IgM Monoclonal Gammopathy of Undetermined Significance
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgG/IgA monoclonal gammopathy of undetermined significance (MGUS).
- Trial name
- NCT07209371
- Testing
- Rifaximin, Biospecimen Collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006379
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Gammopathy, Monoclonal
Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)
Clinical symptoms associated with monoclonal gammapathy have been primarily studied in hematological malignancy and rarely in MGUS and hemopathy.
- Trial name
- GammaClinik (NCT06559579)
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Brest
Multiple Myeloma, Plasma Cell Myeloma
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur…
- Conditions
- Multiple Myeloma, Plasma Cell Myeloma, Precancerous Condition
- Trial name
- NCT00900263
- Testing
- cytogenetic analysis, microarray analysis, biologic sample preservation procedure
- Where
- 69 sites in United States
- Volunteers
- 375 people
- Sponsor
- SWOG Cancer Research Network
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Patients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia
- Trial name
- GEN-HEMO-INF (NCT04702932)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma, Smoldering Multiple Myeloma
European Myeloma Network (EMN) Sample Project
This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma
- Trial name
- EMN36 (NCT06237803)
- Testing
- storage of biological samples
- Where
- 41 sites in Australia, Austria and 8 more
- Volunteers
- 6,000 people
- Sponsor
- European Myeloma Network B.V.
Schnitzler Syndrome
Ilaris (Canakinumab) in the Schnitzler Syndrome
Schnitzler syndrome: Schnitzler syndrome is a rare disabling autoinflammatory syndrome characterized by a chronic urticarial rash and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis or bone pain.
- Trial name
- NCT01245127
- Testing
- Ilaris
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Kidney Failure, Paraproteinemias
The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
The goal of this clinical trial is to learn if drug daratumumab works to treat kidney diseases other than AL-amyloidosis that fall under the category of monoclonal gammopathy of renal significance (MGRS).
- Conditions
- Kidney Failure, Paraproteinemias, Glomerulonephritis
- Trial name
- DAMOCLES (NCT06889948)
- Testing
- Daratumumab
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Helsinki University Central Hospital
Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance
Daratumumab for Polyneuropathy Associated With MGUS
The goal of this clinical trial is to learn about daratumumab and hyaluronidase-fihj in patients with monoclonal gammopathy of undetermined significant (MGUS) who have been diagnosed with peripheral neuropathy suspected to be…
- Trial name
- Dara-MGUS (NCT06046287)
- Testing
- Daratumumab and hyaluronidase-fihj
- Where
- 2 sites in United States
- Sponsor
- Georgetown University